The biotech will stop developing two drugs and lay off nearly three-quarters of its staff after its lead therapy wasn’t as potent in early testing as the company expected.

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...

The newly launched biotech is equipped with rights to a trio of weight loss medicines licensed from China-based Sciwind ...

Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its ...

Barré syndrome, although it said data don’t prove a causal link and affirmed the shots’ benefit outweighs their risks.

Maze fits the mold of biotechs that have pulled off successful offerings recently: The seven-year old startup, which raised ...

Peoria, IL, Jan 8, 2025 — Veloxity Labs, a bioanalytical contract research organization (CRO) specializing in accelerating ...

The Arch-backed startup begins life with several assets acquired from Denali Therapeutics. Elsewhere, Jasper got a negative ...

January 7th, 2025 – Bioforum, The Data Masters, a leading global clinical research organization (CRO) specializing in ...

Zetagen has enlisted Foley & Lardner LLP as its intellectual property counsel and maintains a collaborative professional relationship with Steve Maebius, Esq. Foley & Lardner LLP is a prominent law ...

In 2024, the company forged new partnerships with three of the largest, global pharmaceutical companies in the world, realizing a total of 10 partnerships with leading life science companies. Viz.ai ...